Region — International. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
CJC-1295
Blead outcome
Raises GH / IGF-1 in humans
grades vary by outcome ↓
Peptide⚠ WADA-banned
also called — CJC-1295 · DAC:GRF
GH secretagogue / GHRH analogbody composition (research context)
Research / reference — not for sale. No dosing, reconstitution, or administration is published (intentional). Neutral scientific reference only. A GH secretagogue with a real (and cautionary) clinical-development history.
In brief
CJC-1295 is a long-acting synthetic GHRH analog that reliably raises GH and IGF-1 in humans (shown in a Phase 1 trial). But it has no approved indication — its Phase 2 lipodystrophy programme was halted after a participant death (causation disputed) — and its popular anti-aging / body-composition use has never been tested in humans. Banned in sport.
Legal standing, by region
European Union
Not approved
Not approved; not eligible for magistral/officinal compounding (no Ph. Eur. monograph).
United States
Not FDA-approved (503A Cat. 2)
Placed in 503A Category 2 (2023); its status is in flux amid the 2026 HHS/FDA peptide reclassification, but it is not among the seven peptides in the specific July 23–24 2026 PCAC review; not FDA-approved (IND).
International
Not approved
Not approved.
⚠ WADA-prohibited in sportSport: WADA-prohibited at all times — GHRH analogs / GH secretagogues fall under Section S2.2.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Raises GH / IGF-1 in humans
Pharmacology is real; but raising GH/IGF-1 ≠ a proven clinical benefit
Phase 1 (Teichman 2006) + animal studies · Sustained elevation
BClinical efficacy (lipodystrophy)
Trial terminated after a participant death; no efficacy conclusion reached
Phase 2 (NCT00267527) — halted · Inconclusive
DAnti-aging / body composition / muscle
Extrapolated from GH/IGF-1 changes; never tested for these goals
None in humans · Not demonstrated
FSafety & long-term
Causation disputed; GH/IGF-1 elevation carries theoretical risks (IGF-1/oncologic, insulin resistance, edema); WADA-banned
Limited; a trial-death shadow · Unknown
—Disclosure
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
Evidence changes
Get notified if this changes
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for CJC-1295 changes - nothing else.
Identity
a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the biologically active GHRH(1-29) fragment (the same fragment as sermorelin) with four amino-acid substitutions that resist DPP-4/peptidase cleavage. The DAC version adds a maleimidopropionyl group (via a lysine at position 30) that binds serum albumin, extending half-life from minutes to ~6–8 days. < 40 aa → peptide.
Development & history
- Technology licensed from University of Saskatchewan researchers (early 2000s); developed by ConjuChem Biotechnologies (Canada) on its DAC bioconjugation platform (mid-2000s), targeting GH deficiency, lipodystrophy, and muscle-wasting.
- Phase 1 (Teichman et al. 2006, JCEM): 21 healthy adults, single subcutaneous doses; sustained GH/IGF-1 elevation for up to ~14 days.
- Phase 2 in HIV-associated lipodystrophy (NCT00267527, 192 patients, 2006).
- Discontinued: the Phase 2 programme was halted after one participant's cardiovascular death. The attending physician judged it most likely due to pre-existing asymptomatic coronary disease and unrelated to CJC-1295, but development was terminated as a precaution. (Some sources also cite commercial/manufacturing reasons.)
- Never FDA-approved; classified as an Investigational New Drug; has lived in research/gray-market use since. No modern Phase 2/3 registered as of 2026.
Mechanism (as proposed)
a GHRH-receptor agonist on pituitary somatotrophs → stimulates GH release → downstream IGF-1. The DAC version's albumin binding produces sustained receptor stimulation and elevated baseline GH/IGF-1 (vs the pulsatile signal of sermorelin or the no-DAC form).
Chemical identifiers
Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.
InChIKeyZUQGTWKGESAQCD-ZGFIGYLBSA-N
SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
via PubChem exact-name match (CJC-1295) · high confidence
Sources — 3 cited
01Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006.
02Jette L, et al. (CJC-1295 as a long-lasting GRF analog in rats.) 2005; Alba M, et al. (GHRH-KO mice) 2006; Sackmann-Sala L, et al. (serum protein profile) 2009.
03ConjuChem Phase 2 (NCT00267527).
Updated 2026-07-04
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
Region — International
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.